IWR-1, a tankyrase inhibitor, attenuates Wnt/β-catenin signaling in cancer stem-like cells and inhibits in vivo the growth of a subcutaneous human osteosarcoma xenograft
- PMID: 29126913
- DOI: 10.1016/j.canlet.2017.11.004
IWR-1, a tankyrase inhibitor, attenuates Wnt/β-catenin signaling in cancer stem-like cells and inhibits in vivo the growth of a subcutaneous human osteosarcoma xenograft
Abstract
Wnt/β-catenin or canonical Wnt signaling pathway regulates the self-renewal of cancer stem-like cells (CSCs) and is involved in tumor progression and chemotherapy resistance. Previously, we reported that this pathway is activated in a subset of osteosarcoma CSCs and that doxorubicin induced stemness properties in differentiated cells through Wnt/β-catenin activation. Here, we investigated whether pharmacological Wnt/β-catenin inhibition, using a tankyrase inhibitor (IWR-1), might constitute a strategy to target CSCs and improve chemotherapy efficacy in osteosarcoma. IWR-1 was specifically cytotoxic for osteosarcoma CSCs. IWR-1 impaired spheres' self-renewal capacity by compromising landmark steps of the canonical Wnt signaling, namely translocation of β-catenin to the nucleus and subsequent TCF/LEF activation and expression of Wnt/β-catenin downstream targets. IWR-1 also hampered the activity and expression of key stemness-related markers. In vitro, IWR-1 induced apoptosis of osteosarcoma spheres and combined with doxorubicin elicited synergistic cytotoxicity, reversing spheres' resistance to this drug. In vivo, IWR-1 co-administration with doxorubicin substantially decreased tumor progression, associated with specific down-regulation of TCF/LEF transcriptional activity, nuclear β-catenin and expression of the putative CSC marker Sox2. We suggest that targeting the Wnt/β-catenin pathway can eliminate CSCs populations in osteosarcoma. Combining conventional chemotherapy with Wnt/β-catenin inhibition may ameliorate therapeutic outcomes, by eradicating the aggressive osteosarcoma CSCs and reducing drug resistance.
Keywords: Apoptosis; Cancer stem-like cells; Doxorubicin; IWR-1; Osteosarcoma; Wnt/β-catenin signaling.
Copyright © 2017 Elsevier B.V. All rights reserved.
Similar articles
-
WM130 preferentially inhibits hepatic cancer stem-like cells by suppressing AKT/GSK3β/β-catenin signaling pathway.Oncotarget. 2016 Nov 29;7(48):79544-79556. doi: 10.18632/oncotarget.12822. Oncotarget. 2016. PMID: 27783993 Free PMC article.
-
Cardamonin inhibits the growth and stemness of osteosarcoma stem cells by inducing autophagy and inhibiting the Wnt/β-catenin signaling pathway.Sci Rep. 2025 Aug 12;15(1):29484. doi: 10.1038/s41598-025-14209-3. Sci Rep. 2025. PMID: 40796594 Free PMC article.
-
Efflux inhibition by IWR-1-endo confers sensitivity to doxorubicin effects in osteosarcoma cells.Biochem Pharmacol. 2018 Apr;150:141-149. doi: 10.1016/j.bcp.2018.01.037. Epub 2018 Feb 8. Biochem Pharmacol. 2018. PMID: 29412166 Free PMC article.
-
Phytochemicals as Innovative Therapeutic Tools against Cancer Stem Cells.Int J Mol Sci. 2015 Jul 10;16(7):15727-42. doi: 10.3390/ijms160715727. Int J Mol Sci. 2015. PMID: 26184171 Free PMC article. Review.
-
Self-Renewal and Pluripotency in Osteosarcoma Stem Cells' Chemoresistance: Notch, Hedgehog, and Wnt/β-Catenin Interplay with Embryonic Markers.Int J Mol Sci. 2023 May 7;24(9):8401. doi: 10.3390/ijms24098401. Int J Mol Sci. 2023. PMID: 37176108 Free PMC article. Review.
Cited by
-
The antifibrotic potential of IMT504: modulation of GLAST + Wnt1 + bone marrow stromal progenitors and hepatic microenvironment.Stem Cell Res Ther. 2024 Sep 4;15(1):278. doi: 10.1186/s13287-024-03896-w. Stem Cell Res Ther. 2024. PMID: 39227908 Free PMC article.
-
Norbornene and Related Structures as Scaffolds in the Search for New Cancer Treatments.Pharmaceuticals (Basel). 2022 Nov 25;15(12):1465. doi: 10.3390/ph15121465. Pharmaceuticals (Basel). 2022. PMID: 36558915 Free PMC article. Review.
-
Cancer Stem Cells as a Source of Drug Resistance in Bone Sarcomas.J Clin Med. 2021 Jun 14;10(12):2621. doi: 10.3390/jcm10122621. J Clin Med. 2021. PMID: 34198693 Free PMC article. Review.
-
Covalent Degrader of the Oncogenic Transcription Factor β-Catenin.J Am Chem Soc. 2024 Jun 6:10.1021/jacs.4c05174. doi: 10.1021/jacs.4c05174. Online ahead of print. J Am Chem Soc. 2024. PMID: 38848252
-
ADP-Ribosylation as Post-Translational Modification of Proteins: Use of Inhibitors in Cancer Control.Int J Mol Sci. 2021 Oct 7;22(19):10829. doi: 10.3390/ijms221910829. Int J Mol Sci. 2021. PMID: 34639169 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources